Search bioRxiv⌕ Search

Biology subjects

Takakuwa, J.

Publications and source records attributed to Takakuwa, J..

2 recordsLinked to original sources

A novel multifunctional role for Hsp70 in binding post-translational modifications on clients

Hsp70 interactions are critical for cellular viability and the response to stress. Previous attempts to characterize Hsp70 interactions have been limited by their transient nature and inability of current technologies to distinguish direct vs bridged interactions. We report the novel use of cross-linking mass spectrometry (XL-MS) to comprehensively characterize the budding yeast Hsp70 protein interactome. Using this approach, we have gained fundamental new insights into Hsp70 function, including definitive evidence of Hsp70 self-association as well as multi-point interaction with its client proteins. In addition to identifying a novel set of direct Hsp70 interactors which can be used to probe chaperone function in cells, we have also identified a suite of PTM-associated Hsp70 interactions. The majority of these PTMs have not been previously reported and appear to be critical in the regulation of client protein function. These data indicate that one of the mechanisms by which PTMs contribute to protein function is by facilitating interaction with chaperones. Taken together, we propose that XL-MS analysis of chaperone complexes may be used as a unique way to identify biologically-important PTMs on client proteins. O_LIIn vivo confirmation of Hsp70 dimerization C_LIO_LIComprehensive direct interactome of Hsp70 C_LIO_LIMulti-domain interactions between Hsp70 and client proteins C_LIO_LIIdentification of novel biologically-important client protein PTMs C_LI

molecular biology↗

Chemogenomic screening Identifies the Hsp70 Co-chaperone HDJ2 as a Hub for Anticancer Drug Resistance

Heat shock protein 70 (Hsp70) is an important molecular chaperone that regulates oncoprotein stability and tumorigenesis. However, attempts to develop anti-chaperone drugs targeting molecules such as Hsp70 have been hampered by toxicity issues. Hsp70 is regulated by a suite of co-chaperone molecules that bring \"clients\" to the primary chaperone for efficient folding. Therefore, rather than targeting Hsp70 itself, here we have examined the feasibility of inhibiting the co-chaperone HDJ2, a member of the J domain protein family, as a novel anticancer strategy. We found HDJ2 to be upregulated in a variety of cancers, suggesting a role in malignancy. To confirm this role, we screened the NIH Approved Oncology collection for chemical-genetic interactions with loss of HDJ2 in cancer. 41 compounds showed strong synergy with HDJ2 loss, whereas 18 dramatically lost potency. Several of these hits were validated using a HDJ2 inhibitor (116-9e) in castration-resistant prostate cancer cell (CRPC) and spheroid models. Taken together, these results confirmed that HDJ2 is a hub for anticancer drug resistance and that HDJ2 inhibition may be a potent strategy to sensitize cancer cells to current and future therapeutics.\n\nGraphical AbstractHDJ2 knockout or inhibition via small molecule impacts cellular resistance to anticancer therapeutics.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=200 SRC=\"FIGDIR/small/818427v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (86K):\norg.highwire.dtl.DTLVardef@cc1f42org.highwire.dtl.DTLVardef@1184229org.highwire.dtl.DTLVardef@19f9b8aorg.highwire.dtl.DTLVardef@19c9037_HPS_FORMAT_FIGEXP M_FIG C_FIG

cancer biology↗